

## SUBJECT INDEX TO VOLUME 5

Acromegaly .....	277	effects on metabolism .....	442
dopamine agonists for .....	279	effects on transcription .....	442
growth hormone receptor antagonists for .....	279	in energy balance .....	441
medical therapy of .....	279	in hypothalamus .....	443
radiation therapy of .....	278	AMPK- <sub>2</sub> .....	460
somatostatin agonists for .....	279	isoform regulates transcription of .....	460
surgical therapy of .....	278	nuclear localization of .....	461
treatment options for .....	278	AMP kinase family .....	533
Acute GVHD mice.....	580	AMP-activated protein kinase as.....	533
IFN- blockade in.....	580	salt-inducible kinase (SIK) as.....	533
relate to human HSC transplantation .....	582	Angiotensinogen .....	295
TNF- blockade in.....	580	Antagonistic IL(P40) .....	272
Acylation-stimulating protein (ASP) .....	294	to block IL-12 functions .....	272
Adipocyte trypsin (adipsin).....	294	Anti-diabetic drugs.....	469
Adipokines .....	295	clinical view of .....	469
Adiponectin .....	294	need to develop.....	469
Adipose tissue .....	293	Anti-diabetic therapy.....	499
endocrine function of .....	293	Anti-inflammatory agents .....	335
Agonistic IL-12(P40-P35) fusion protein .....	270	ApoA-I mimetic peptides as .....	335
to counteract TH2 polarization .....	270	Antioxidant therapy.....	254
A-I <sub>milano</sub> .....	324	experimental arthritis.....	254
clinical studies with .....	326	Apo A-I .....	315,324,335
in myocardial damage .....	324	clinical studies with .....	326
reperfusion injury protection by .....	324	fibrinolytic activity of .....	324
Albugon.....	491	Apo A-I mimetic peptides .....	336
Allogeneic hematopoietic stem cell transplantation .....	555	anti-inflammatory properties of .....	336
clinical trials of.....	560	search for .....	336
immune reaction relevant to.....	555	Apo A-I/PC discs .....	315
<i>in vitro/in vivo</i> sirolimus for.....	555	Arachidonic acid .....	242
inhibition of GVHD by .....	558	Aromatase .....	294
modulation of .....	555	Atherosclerosis .....	47,295,315
sirolimus molecular mechanisms of action for .....	557	effect of Apo A-I peptides on.....	317
AMP-activated proteins kinase .....	451,459	effect of PC discs on .....	318
and role of AICAR .....	455	effect of HDLs on.....	315
and role of metformin .....	455	effect of intravenous Apo A-I on .....	315
and role of thiazolidinediones .....	455	effect of lipid-free Apo A-I on .....	317
as anti-diabetes drug target .....	451,454	in animals .....	315
as negative regulator of protein synthesis .....	463	in humans .....	315
direct modulation of transcription factor		mechanisms of endothelial dysfunction in .....	50,51
activity by .....	462	natural history of plaque development in .....	47
downstream effects of activation of .....	453	pathogenesis of .....	48
function of .....	451	pathology of.....	47
hormonal regulation of .....	453	progression in humans.....	48
in maintenance of cellular energy balance .....	451	regulation of coagulation/fibrinolysis in .....	49
in regulation of metabolic gene expression .....	459	role of endothelium in initiation/development of.....	47,49
in transcriptional control .....	459	therapeutic implications of .....	51
modulation of coregulator function by .....	462	time-course of.....	48
regulation by AMP .....	453	Autoimmunity .....	86
regulation of mRNA stability by .....	463	connection with immunity .....	86
role in whole body energy balance .....	453	Bone marrow transplantation (BMT).....	547
small molecule activators of .....	455	diseases curable by .....	554
structure of .....	451	translational research for .....	553
AMP-activated protein kinase pathway .....	439		
as target for obesity therapy .....	439		

cAMP response element binding protein (CREB) .....	445	lactone-based inhibitors of .....	350
Cancer .....	61	pyridyltetrahydronaphthyl inhibitors of .....	347
animal models of .....	66	quinoline inhibitors of .....	353
apoptosis in .....	64	search for synthetic inhibitors of .....	341
curcumin in .....	67	sulfur-containing inhibitors of .....	346
dietary chemopreventive agents in .....	62	Chronic degenerative diseases .....	149
dietary phytochemicals in .....	61	inflammatory status in .....	149
(-)-epigallocatechin-3-gallate (EGCG) in .....	68	strategies to decrease inflammation in .....	153
genistein in .....	67	Chronic GVHD mice .....	580
human studies of .....	66	relate to human lupus .....	580
MAP kinase pathways in .....	62	Chronic subclinical inflammation .....	149
methods in chemoprevention of .....	61,65	antiinflammatory agents in foods for .....	153
NF- B in .....	62	antiinflammatory drugs in .....	153
quercetin in .....	69	aspirin in .....	153
resveratrol in .....	69	drugs for .....	149
Cardiovascular diseases .....	321	foods for .....	149
apolipoprotein A-I for .....	322	in humans .....	149
apolipoprotein A-I <sub>milano</sub> for .....	322	NF- B/insulin signaling in .....	151
development of recombinant apolipoproteins for .....	322	other non steroidal anti-inflammatory drugs	
high-density lipoproteins (HDL) for .....	321	(NSAID) in .....	153
therapeutic modality for .....	321	other phenolic compounds for .....	153
treatment of .....	321	CJC-1131 .....	491
Cardiovascular risk .....	339	Clinical coronary atherosclerosis .....	318
high density lipoprotein (HDL) in .....	339	Colon cancer .....	54
Cell surface GLUT4 transporters .....	176	and physical activity .....	54
biotinylation of .....	176	anthropometric risk factors of .....	54
photoaffinity labelling with ATB-BMPA .....	176	insights from epidemiologic studies of .....	55
c-FOS pathway .....	445	metabolic conditions associated with .....	54
Chemoprevention .....	61	role of nutrition in .....	57
effect of ARE/EpRE signaling on .....	64	Coronary heart disease (CHD) .....	3
effect of -catenin pathway on .....	64	as inflammatory disease .....	9
effect of TGF- pathway on .....	64	by deficiency in specific micronutrients .....	7
historical perspective of .....	61	dietary prevention of .....	3
Childhood epilepsy .....	113	effect of cytokines on .....	8
antiepileptic drugs for .....	113,114,117	effect of dietary fatty acids on .....	8
carbamazepine (CBZ) to treat .....	117	effect of fatty acids on .....	5
effect of poly-unsaturated fatty acids (PUFA)		effect of left ventricular hypertrophy on .....	9
plasmatic concentration on .....	116	effect of oleic acid on .....	5
lamotrigine (LTG) to treat .....	117	effect of saturated fatty acids on .....	5
nutritional/pharmacological management of .....	113	effect of sodium intake on .....	8
phenytoin (PTH) to treat .....	117	effect of <i>trans</i> fatty acids on .....	5
role of ketogenic diets in .....	113	lipid oxidation theory of .....	9
topiramate (TPM) to treat .....	117	COX-1 .....	243
valproate (VPA) to treat .....	117	COX-2 .....	243
vigabatrin (VGB) to treat .....	117	COX-2 isoforms .....	243
Cholesteryl ester transfer protein (CETP) .....	339	COX-2 selective inhibitors .....	241
agents for inhibition of .....	339	cardiovascular risk of .....	246
aminopropanol inhibitors of .....	351	development of .....	241,243
clinical trials of inhibitors of .....	345	gastrointestinal safety of .....	246
deficiency in atherosclerosis .....	344	renal effects of .....	246
deficiency of .....	340	therapeutic perspectives of .....	241
di-benzyl amine inhibitors of .....	350	Coxibs .....	244
effect of lipid transfer on .....	341	Diabetes mellitus .....	469
in treatment of atherosclerosis .....	339	pathophysiology of .....	469
inhibition in humans .....	354	targeting insulin deficiency in .....	472
inhibition of .....	344		
inhibitors as therapeutic agents .....	355		

targeting insulin resistance in.....	470	effect in CD4 <sup>+</sup> T helper cell polarization.....	86
targeting lipid metabolism in .....	472	effect on autoantibody production .....	88
targeting obesity in.....	472	effect on cytokine production during autoimmunity	86
Diet.....	9	effect on differentiation of hematopoietic cells .....	89
in prevention of plaque inflammation/rupture.....	9	effect on B lymphocyte function .....	88
Dietary potassium .....	21	effect on Sjogren's syndrome .....	88
against hypertension .....	25	effect on systemic lupus erythematosus .....	88
animal studies of.....	27	in autoimmune disease.....	85
clinical trials of supplementation of .....	24	in immunity.....	85
effect on blood pressure.....	23	metabolism of .....	88
effect on cardiovascular diseases.....	26	role in collagen induced arthritis .....	87
extrarenal handling of.....	22	role in multiple sclerosis/EAE.....	86
human studies of.....	26	role in rheumatoid arthritis .....	87
in cardiovascular prevention.....	21	Estrogen receptor modulators .....	89
nutritional/clinical implications of .....	21	strategies to modulate autoimmunity <i>via</i> .....	89
renal handling of.....	22	Estrogen therapy.....	89
Dietary salt.....	13	strategies to modulate autoimmunity <i>via</i> .....	89
and public health strategy in developed		ETC-216 .....	328
countries .....	18,19	clinical studies of .....	328
global perspective for .....	13	Eutherian relaxin .....	383
in cardiovascular diseases .....	13	evolution of .....	383
in disease prevention .....	13	Exenatide.....	490
in hypertension .....	13	clinical data of .....	490
DPP 4 inhibitors .....	485	preclinical data of.....	490
clinical data of.....	492	Experimental atherosclerosis .....	49
in treatment of type 2 diabetes .....	485	endothelial dysfunction in.....	49
Dysfunctional HDL .....	343		
		Fatty acid metabolism .....	439
Elevated homocysteine .....	125	as target for obesity therapy .....	439
as risk factor for vascular disease.....	125,130	Fatty acid synthase .....	439
influence of disease state on.....	134	as pharmacological target .....	440
pharmacological doses of B-vitamins in.....	132	as target for weight loss .....	440
physiological doses of B-vitamins in .....	132	central mechanism of .....	441
treatment of.....	125	for modulation of feeding behavior .....	440
Endothelial cell function .....	318	in cancer cells .....	445
effect of ApoA-I/PC discs on .....	318	in cancer therapy .....	440
Endothelial dysfunction .....	50	peripheral mechanism of .....	441
risk factor for acute thrombotic complication .....	50	Fatty acid synthesis .....	439
to find tissue injury following acute thrombosis .....	51	Feeding behavior .....	444
Endothelium.....	48	CNS pathways of .....	444
physiology of.....	48	Female reproduction system .....	383
regulation of circulating cells by .....	49	relaxin in .....	383
therapeutic implications of .....	51		
Enzymes.....	104	Glimepiride .....	499
as dampeners .....	104	as antidiabetic drug.....	499
Epilepsy.....	113	blood-glucose decreasing/insulin-releasing	
antiepileptic drugs to treat .....	117	activity of.....	499
carbamazepine (CBZ) to treat.....	117	clinical advantages of .....	513
ketogenic diet in .....	113	extrapancreatic activity of .....	501,513
lamotrigine (LTG) to treat.....	117	induced redistribution of acylated signaling	
phenytoin (PTH) to treat.....	117	proteins .....	510
topiramate (TPM) to treat.....	117	induced redistribution of GPI-proteins.....	509
valproate (VPA) to treat .....	117	induced stimulation of GPI-PLC.....	505
vigabatrin (VGB) to treat.....	117	insulin mimetic activity of.....	504
Estrogen .....	85	insulin secretion by.....	499
biology of.....	85	insulin-sensitizing activity of .....	502

mode of action of .....	499	gene expression of .....	207,219
molecular mechanisms of .....	502	gene regulation of .....	207,212
physiological relevance of extrapancreatic		in aging .....	209
activity of .....	511	in obesity .....	209,211
signaling pathway in adipose cells .....	505	internalization of .....	168
Glucagons-like peptide 1 (GLP-1) .....	485	intrinsic activity in DM2 .....	208
in treatment of type 2 diabetes .....	485	intrinsic activity in pathophysiological states ..	175,208
strategies for prolonging/half lives/action of .....	490	localisation by immunoelectron microscopy .....	176
therapeutic action of .....	486	localisation by immunofluorescence .....	176
Glucose .....	177	localisation detection <i>via</i> extracellular epitope .....	176
deoxyglucose uptake of .....	177	localisation of .....	168
3- <i>O</i> -methylglucose uptake of .....	177	mechanisms underlying intrinsic activity of .....	185
Glucose homeostasis .....	193	methods to measure rate of glucose uptake by .....	177
and transgenic models .....	193	regulation by PAX3/FKHR in skeletal muscle	
tissue specific transgenic models to study .....	194	sarcoma .....	213
Glucose transport .....	209,522	regulation by RET/PTC in thyroid carcinoma .....	214
carbohydrate mediated regulation of .....	522	regulation by tumor suppressor p53 .....	214
transporter activation of .....	209	regulation in dyslipidemia .....	212
Glucose transport regulators .....	519	regulation in tumorigenesis .....	213
Glucose transporters (GLUTs) .....	189	regulation of .....	175
development of .....	199	regulation of expression by exercise .....	220
global knockout (conventional knockout) to study ..	190	regulation of expression during insulin-deficiency ..	219
in cardiac hypertrophy/function .....	199	regulation of expression <i>in vitro</i> .....	220
in cardiovascular disease .....	201	regulation of intrinsic activity of .....	184
in diabetes .....	201	regulation of transcription of .....	219
inducible tissue specific knockouts to study .....	191	steady state distribution of .....	168
tissue specific knockout (conditional knockout)		trypsin digestion in intact cells .....	176
to study .....	190	GLUT4 gene promoter .....	221
transgenic mouse models to study .....	189	domain I binding proteins at .....	223
using cre-LoxP technology for .....	191	identification of promoter regulatory elements of ..	221
Glucose uptake .....	183	MEF2 domain binding proteins at .....	223
and interaction of drugs .....	184	transcriptional regulation of .....	221
by post-transport events .....	183	GLUT4 global knockout .....	196
GLUT4 .....	159,168,175,207,219	GLUT4 null mice .....	197
and exofacial epitopes .....	184	compensatory glucose uptake in skeletal	
and gender .....	211	muscle by .....	197
and PPAR .....	212	GLUT4 traffic .....	167
and role of CBL/CAP/APS complex .....	162	current model in muscle cells .....	170
and role of CBL/PI 3-kinase .....	163	input of class 1A PI3-K in .....	169
and role of CBL/TC10-dependent pathway .....	162	perspectives from cultured muscle cells .....	167
and role of downstream serine kinases .....	161	role of actin in .....	169
and role of inositol lipid phosphatases .....	161	role of VAMPs in .....	169
and role of insulin receptor substrates .....	159	GLUT4 translocation .....	167,175
and role of insulin receptor tyrosine kinase .....	159	and interaction of drugs .....	184
and role of PI 3-kinase .....	161	comparison of rates of glucose uptake with .....	177
and role of PI 3-kinase/actin remodeling .....	163	insulin signals leading to .....	167
and role of PI 3-kinase-dependent pathway .....	159	methods for measuring .....	175
and role of protein tyrosine phosphatases .....	161	using membrane fractions .....	183
and role of recruitment to lipid rafts .....	162	GPCR receptors .....	411
and role of TC10 effectors .....	163	mouse mutants of .....	411
and role of TC10 GTPase .....	162	Graft failure .....	547
and thiazolidinediones .....	212	crucial role of CD8 <sup>+</sup> cells in prevention of .....	549
detection in subcellular membrane fractions .....	175	prevention by IBM-BMT + donor lymphocyte	
dynamic behaviour of .....	168	infusion .....	547
effect of photolabeling on .....	184	Graft rejection .....	559
endocytosis of .....	168	animal models of .....	559
exocytosis of .....	168	clinical studies of .....	559
function of .....	207	sirolimus inhibition of .....	559

Graft versus host disease (GVHD) .539,547,555,565,575,585	
activation/expansion of donor anti-host	
reactive T cells in .....	586
acute type .....	576
allogeneic hematopoietic cell transplantation in .....	585
animal models of .....	558
as model for study of <i>in vivo</i> immunomodulation ..	579
B7-CD28 in .....	578
biological effects of HGF in .....	567
blocked of inflammatory stimuli/effectors in .....	543
bone marrow transplantation methods for .....	547
CD80 blockade in .....	579
cellular/inflammatory effectors in .....	541
chronic type .....	575
clinical phenotype of acute type .....	575,576
clinical studies of .....	558
complication in .....	585
CTL effector generation in .....	578
cytokine secretion in .....	540
damage/activation of host tissues in .....	586
donor T cell activation in .....	540
early surrogate markers of .....	576
effect of DLI on .....	548
effect of IBM-BMT on .....	549
effects of HCT conditioning in .....	540
FTY70 in .....	570
growth factors for .....	566
IL-2 blockade in .....	579
immunopathogenesis of .....	575
<i>in vitro</i> CTL function in .....	576
modulation of donor T cells in .....	542
parent-into-F1 model of .....	575
prevention of .....	542,547
protective cytokines for .....	566
protective growth factors for .....	565
reduced intensity conditioning regimens in .....	542
regulation of .....	587
rIL-12 administration in .....	579
risk factor of .....	542
role of CTL in .....	578
role of HGF in pathophysiology of .....	568
role of inflammatory cytokines for .....	565
role of platelet derived factors in .....	570
stage-1 of .....	587
stage-2 of .....	588
stages of disease development of .....	586
studies of Naïve T cell activation/costimulation in ..	578
Heart failure .....	7
by deficiency in specific micronutrients .....	7
diet/risk of .....	7
following AMI .....	7
Hematopoiesis .....	567
regulatory role of HGF for .....	567
Hemostasis .....	318
effect of Apo A-I/PC discs on .....	318
Hexoses .....	522
High density lipoprotein .....	309,315,321,361
administration of .....	321
and role of fibrates .....	310
and role of n-3 fatty acids .....	310
and role of nicotinic acid derivatives .....	310
and role of questran .....	310
and role of torcetrapid .....	310
dietary factors .....	361
effect of alcohol on .....	364
effect of dietary carbohydrate on .....	363
effect of dietary cholesterol on .....	363
effect of obesity on .....	364
effect of weight reduction on .....	364
role of HMG CoA reductase inhibitors .....	309
trials of .....	310
Homocysteine .....	125
as risk factor for vascular disease .....	130
determinants of .....	125
effect of drug therapy on .....	129
effect of lifestyle on .....	129
genetic determinants of .....	126
in disease states .....	129
influence of genetic factors on .....	133
metabolism of .....	125
nutritional determinants of .....	128
Homocysteine induced vascular disease .....	131
mechanisms for .....	131
Hyperhomocysteinemia .....	132
nutritional/pharmacological approaches for .....	132
treatment of .....	132
Hyperinsulinemia .....	53
in cancer causation .....	53
interrelations with IGF axis .....	57
role of nutrition in .....	57
Hypothalamus .....	444
appetite regulation by .....	444
IGF-1 receptor .....	214
regulates GLUT4 during early bone formation .....	214
Immunity .....	567
regulatory role of HGF for .....	567
Incretin hormones .....	489
degradation of .....	489
Incretin mimetics .....	485
advantages of .....	492
in treatment of type 2 diabetes .....	485
Inflammation .....	150,295
molecular pathogenesis of .....	150
nuclear factor (NF)- B in .....	151
Inflammatory component .....	149
in cardiovascular disease .....	149
in diabetes .....	150
in neurodegenerative diseases .....	150
in obesity .....	150
Inflammatory signaling mediators .....	252
ROS as .....	252

INSL3 mutants .....	414	LDLs .....	318,377
INSL3 receptor mutants .....	415	effect of Apo A-I/PC discs on .....	318
INSL3 transgenics .....	416	module of .....	377
INSL3-LGR8 hormonal system .....	421	Leptin .....	295
in cryptorchidism .....	421	Leucine-rich repeats .....	376
in humans .....	421	Lipid metabolism .....	444
in testicular descent .....	421	role of PPARs in .....	444
in testicular functions .....	421	Lipototoxicity .....	212
paracrine/endocrine role of .....	426	Liraglutide .....	491
Insulin .....	202,208	clinical data of .....	491
activation of .....	208	preclinical data of .....	491
secretion of .....	202	Long-acting basal insulin analogs .....	478
Insulin analogs .....	475	insulin detemir as .....	479
and role of IGF-I receptors .....	481	insulin glargine as .....	478
and role of insulin receptors .....	482	Malignant tumor .....	550
in tumor cells .....	482	IBM-BMT + DLI for treatment of .....	550
safety issues of .....	481	Malonyl -CoA paradox .....	441
Insulin dependent type I diabetes .....	88	Mediterranean diet .....	33
murine model of .....	88	antioxidant properties of .....	33
Insulin receptor .....	520	as Greek food .....	33
agonists/enhancers of .....	520	beneficial components of .....	33
Insulin resistance .....	53	consumption of fish in .....	35
in cancer causation .....	53	flavonoid content of .....	33
role of nutrition in .....	57	flavonoid intake in .....	37
Insulin resistance syndrome .....	56	high consumption of legumes in .....	35
and other cancers .....	58	high consumption of non-refined cereals in .....	35
role of nutrition in .....	57	high consumption of olive oil in .....	34
Insulin responsive glucose transporter .....	207	high consumption of vegetables/fruits in .....	34
Insulin signaling pathway .....	159,532	low consumption of milk/dairy products in .....	36
glycogen synthase kinase-3 (GSK3) in .....	532	low intake of meat/meat products in .....	37
mTOR-S6K1 pathway of .....	532	moderate intake of alcohol in .....	36
regulating translocation of GLUT4 .....	159	Metabolic engineering .....	103
Insulin syndrome .....	54	from vitamins to drugs .....	106
metabolic conditions associated with .....	54	Metabolic master genes .....	107
role of nutrition in .....	57	use of .....	107
Insulin-like 3 peptide .....	411	Niacin .....	311
mouse mutants of .....	411	and statins .....	311
Insulin-responsive glucose transporter .....	207	familial atherosclerosis treatment trial of .....	311
disregulation of .....	207	in combination therapy .....	311
in abnormal metabolic states .....	207	monotherapy by .....	311
Interleukin-6 .....	294	Non-reproductive tissues .....	391
Ischaemic heart disease .....	311	actions of relaxin on .....	391
bezafibrate intervention study in .....	311	Novel somatostatin agonists .....	277
clofibrate in .....	311	application in acromegaly .....	277
primary prevention of .....	311	GH-inhibitory activity of .....	277
Ketogenic diet .....	114	NPY .....	445
alteration in neurotransmitter function by .....	115	NSAIDs .....	243
alterations in brain extracellular milieu by .....	116	Nuclear receptors .....	74
changes in ionic currents by .....	115	effect of diet on expression of .....	79
indications of use of .....	117	role in metabolism .....	74
mechanisms of action of .....	114		
other application of .....	121		
side effects of .....	119		

Obesity .....	73,439	use of opioids in .....	232
development of synthetic FAS inhibitors for .....	440	use of oral glucosamine in .....	233
role of peroxisome proliferator-activated receptors .....	74	use of other agents in .....	233
role of estrogen/androgen receptors in .....	79	use of pentosan polysulfate in .....	235
role of glucocorticoid receptor in .....	80	use of selective COX-2 inhibitors in .....	232
role of orphan nuclear receptors/cofactors in .....	80	use of tetracyclines in .....	234
role of PPAR .....	75	use of tramadol in .....	232
role of PPAR .....	76	Oxidation pathways .....	439
role of PPAR .....	74	PAI-1 .....	295
role of PPAR modulators in .....	77	Parent-into-F1 model .....	575
role of retinoid X receptor in .....	77	as model of <i>in vivo</i> T cell function .....	575
targeting nuclear receptors .....	73	immunomodulation as .....	575
Osteoarthritis (OA) .....	229,259	use for elucidation of normal T cell function	
aggrecan in .....	266	<i>in vivo</i> .....	577
aggrecanase in .....	266	Pentoses .....	524
anabolic mediators in .....	237	Peroxisomes .....	444
bone-cartilage interactions in .....	236	Pharmacotherapy .....	309
characteristics of pain in .....	230	of HDL cholesterol .....	309
crystals in .....	236	Phytochemicals .....	61
cytokines in .....	235	chemopreventive activity of .....	67
disease/structure-modifying treatment for .....	234	Phytoestrogen .....	141
disease progression of .....	234	adverse effects on infant development .....	145
DMARD therapy for .....	264	adverse effects on thyroid gland .....	145
DMOADs for .....	264	clinical effects of .....	142
emerging targets of .....	259	effects on bone .....	143
glycosaminoglycans (GAG) in .....	264	effects on breast .....	144
hyaluronic acid in .....	265	effects on heart disease .....	144
intra-articular chondrocyte transplantation		effects on uterus .....	144
therapy for .....	236	estrogenic effects of .....	141
joint innervation in .....	230	in human health .....	141
mechanism of pain in .....	230	in men .....	145
mesenchymal stem cell therapy for .....	236	metabolism of .....	142
MMP-13 in .....	266	sources of .....	141
nitric oxide in .....	236	PI 3-kinase pathways .....	161
pain perception in .....	230	negative regulation of .....	161
pathogenesis of .....	234	Plant metabolism .....	103
perlecan in .....	266	engineering of .....	103
preventing matrix degradation in .....	266	for drug .....	103
preventing proteoglycan loss/glycosaminoglycan		for food .....	103
supplementation in .....	264	Plasma lipoproteins .....	317
promoting cartilage repair/regeneration in .....	236	effect of Apo A-I/PC discs on .....	317
proteinases in .....	235	Platelets .....	318
signal transduction molecules in .....	235	effect of Apo A-I/PC discs on .....	318
sources of pain in .....	230	Potassium homeostasis .....	21
structural changes in .....	234	regulation of .....	21
symptomatic treatment of pain in .....	231	Prostanoids .....	242
symptomatic type .....	229	biosynthesis of .....	242
targeting catabolic processes in .....	235	in inflammation .....	243
therapeutics of .....	229,259	Rapid-acting insulin analogs .....	476
use of acetaminophen in .....	231	insulin aspart as .....	478
use of artemparon in .....	234	insulin glulisine as .....	478
use of chondroitin sulfate in .....	233	insulin lispro as .....	476
use of diacerein in .....	235		
use of glycosaminoglycan/peptide complex			
(GAG-peptide/rumalon in .....	234		
use of intra-articular (IA) nonsteroidal agents in .....	233		
use of intra-articular (IA) steroids in .....	232		
use of NSAIDS in .....	231		
use of nutraceutical agents in .....	233		

Recombinant interleukin-12.....	269	in mammary gland .....	434
for immunotherapy.....	269	in neoplastic lesion .....	431
Relaxin .....	370,383,391,403,411	in thyroid gland .....	433
airway remodeling effect of .....	397	INSL3 as.....	373
antifibrotic effect of .....	394,395,396	INSL4 as .....	373
cardio-protective effect of .....	393	INSL5 as .....	374
chronotropic-inotropic effect of .....	393	INSL6 as .....	374
clinical aspects of .....	403	modern perspectives on .....	369
double mutants .....	416	structure of .....	369
effect on brain .....	397	Relaxin receptor (Lgr7) mutants .....	413
effect on cardiovascular system .....	391	Resistin.....	294
effect on liver .....	399	Reverse cholesterol transport .....	299,317
effect on other non-reproductive organs .....	400	ABC transporter in .....	300
effect on renal system .....	395	acyl-coenzyme A in .....	301
effect on respiratory system .....	396	apolipoprotein A-I in .....	302
effect on skin .....	399	caveolin-dependent pathway of .....	301
fluid homeostasis by .....	398	cholesterol acyltransferase (ACAT) in .....	301
hyperfiltration effect of .....	396	cholesterol efflux in .....	300
in allergic diseases .....	407	cholesterol excretion in .....	304
in cardiovascular diseases .....	405	CYP27A1-dependent pathway of .....	301
in fibrosis diseases .....	405	diffusion pathway of .....	300
in gastrointestinal motor diseases .....	408	effect of Apo A-I/PC discs on .....	317
in implantation .....	384	flux of cholesterol through plasma in.....	302
in inflammatory diseases .....	407	HDL cholesterol uptake in .....	304
in myometrial function .....	387	in atheroprotection.....	299
in obstetrics .....	403	lecithin in .....	302
in periparturient widening of birth canal .....	387	lipases in.....	303
in rupture of fetal membranes .....	387	phospholipid transfer protein in .....	303
in stem cell differentiation .....	407	role of cholesteryl ester transfer protein in.....	302
in vascular control .....	384	role of high density lipoprotein in.....	299
mouse mutants of .....	411	SR-BI-dependent pathway of .....	301
myocyte-myocyte interaction mediated effect of ...	395	therapeutic targeting of HDL in .....	299
myogenic reactivity effect of .....	396	Rheumatoid arthritis.....	249,259
other effects in brain .....	399	aggrecan in .....	266
regulation of action of .....	387	aggrecanase in .....	266
regulation of oxytocin secretion by .....	398	animal studies of.....	252
regulation of plasma osmolality by .....	398	antioxidant-based treatments in.....	256
renal vasodilation effect of.....	396	as inflammatory disease .....	249
sodium excretion effect of .....	396	assessment of disease severity of .....	260
therapeutic perspectives of .....	403	biologics in .....	260
transgenics of .....	414	clinical studies of.....	255
vasodilatory effect of .....	392	corticosteroids in .....	260
vasopressin secretion by .....	398	cytokine related targets of .....	263
wound healing effect of .....	393	disease modification in.....	259
Relaxin-3.....	377	DMARD therapy for .....	249,264
Relaxin family peptides .....	370	DMARD in progress for .....	260,263
Relaxin family receptors .....	374	effect of oxidative stress on.....	249
GPCR135 as .....	377	emerging targets of.....	259
GPCR142 as .....	377	hyaluronic acid in .....	265
INSL3 receptors as .....	376	immunosuppressant in .....	260
INSL5 as .....	377	leflunomide in .....	260
LGR7 as .....	376	markers of oxidant stress in .....	255
LGR8 as .....	376	methotrexate in .....	260
structure to function of .....	376	MMP-13 in .....	266
Relaxin-like peptides .....	369,431	NSAIDs in.....	260
evolution of .....	369	oxidant stress in.....	252
function of .....	369	pathogenesis of.....	250
in male reproductive tract .....	431	pathophysiology of.....	259
		perlecan in .....	266

preventing matrix degradation in .....	266	promoting cartilage repair/regeneration in .....	236
preventing proteoglycan loss/glycosaminoglycan supplementation in .....	264	proteinases in .....	235
signal cascade inhibitors in .....	263	signal transduction molecules in .....	235
small molecule drugs for .....	260	structural changes in .....	234
sources of reactive oxygen species in .....	250	targeting catabolic processes in .....	235
T/B cell response inhibitors in .....	263	use of arteparon in .....	234
treatment of .....	249,259	use of diacerein in .....	235
use of antioxidants for .....	249,255	use of glucosamine/chondroitin sulfate in .....	235
vitamin supplementation in .....	256	use of glycosaminoglycan/peptide complex (GAG-peptide/rumalon) in .....	234
Salicylates .....	214	use of pentosan polysulfate in .....	235
and IKK-NFKB pathway .....	214	use of tetracyclines in .....	234
Salt reduction .....	15	Sudden cardiac death .....	3
at population level .....	17	dietary prevention of .....	3
to reduce blood pressure .....	15	effect of alcohol on .....	5
Serine kinases .....	529	effect of antioxidants on .....	6
as drug targets .....	529	effect of fish eating on .....	3
for treatment of type 2 diabetes .....	529	effect of n-3 fatty acids on .....	3
in inflammation .....	529	effect of n-6 fatty acids on .....	5
in insulin action .....	529	effect of oleic acid on .....	5
in metabolic diseases .....	529	effect of saturated fatty acids on .....	5
Jun kinase-1 (JNK-1) as .....	530	effect of <i>trans</i> fatty acids on .....	5
KappaB kinase-2 (IKK2) as .....	531	Sulfonylurea treatment .....	514
protein kinase C theta as .....	530	future perspectives of .....	514
Sex hormones .....	85	Symptomatic osteoarthritis .....	229
effects on immune function in health/disease .....	85	in pain .....	229
Sirolimus .....	558	TC10 .....	163
cellular targets of .....	558	atypical PKCs as targets for .....	163
Somatostatin .....	280	Tissue specific GLUT4 knockout models .....	198
antisecretory activity of .....	282	in adipose .....	199
biological functions of .....	280	in skeletal muscle .....	198
clinical efficacy in acromegaly .....	287	Transcription .....	463
GH-inhibitory activity of .....	284	role of / regulatory subunits in .....	463
GH regulation by .....	280	Tumor growth .....	550
receptor for .....	281	effects of IBM-BMT plus DLI on .....	550
signaling pathways of .....	282	Tumour necrosing factor- .....	293
Soy .....	145	Type 2 diabetes .....	485
effects on diabetes .....	145	incretin action in .....	485,486
Soy/red clover derived phytoestrogen .....	142	incretin secretion in .....	486
effects on climacteric symptoms .....	142	role of DPP 4 inhibition in .....	491
Sphingosin-1-phosphate (SIP) .....	568	side effects of .....	492
biological effects of .....	568	Vascular disease .....	134,322
in pathophysiology of .....	569	primary prevention of .....	134
regulatory role for hematopoiesis/immunity .....	568	use of APOA-I <sub>milano</sub> in treatment of .....	322
Structural osteoarthritis .....	234	Vascular metabolism .....	315
anabolic mediators in .....	237	effect of Apo A-I peptides on .....	317
bone-cartilage interactions in .....	236	effect of Apo A-Imilano on .....	316
crystals in .....	236	effect of Apo A-Imilano/PC discs on .....	318
cytokines in .....	235	effect of Apo A-I/ phospholipid discs on .....	315
disease/structure-modifying treatment for .....	234	effect of HDLs on .....	315
disease progression of .....	234	effect of intravenous Apo A-I on .....	315
intraarticular chondrocyte transplantation therapy for .....	236	effect of lipid-free Apo A-I on .....	317
mesenchymal stem cell therapy for .....	236	in animals .....	315
nitric oxide (NO) in .....	236	in humans .....	315
pathogenesis of .....	234		

Vascular protection .....	312	Vasodilator mediators .....	48
mechanisms of .....	312	EDHF as.....	49
Vasoconstrictor mediators .....	49	nitric oxide as.....	48
endothelins as .....	49	prostaglandins as.....	49